Back Login to subscribe 🔔 Set Alert

SPRC SciSparc Ltd. Ordinary Shares

15 min delay

Loading...

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	12 Health Care Stocks Moving In Monday's After-Market Session	96.23%
	SciSparc shares are trading higher after the company announced its subsidiary, NeuroThera labs, continued advancement in participant enrollment for the clinical trial assessing the SCI-210 treatment for symptoms associated with autism spectrum disorder	95.45%
	SciSparc Says NeuroThera Labs Advances Participant Enrollment For Clinical Trial Assessing SCI-210 Treatment For Symptoms Associated With Autism Spectrum Disorder	73.65%
	SciSparc Adds Prof. Carmel Domshlak To Newly Established Scientific Advisory Board For AI And Cybersecurity, Effective September 1	72.7%
	SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders	84.04%
	SciSparc shares are trading higher. The company announced its majority-owned subsidiary, NeuroThera Labs, has completed two tranches of non-brokered private placements, raising aggregate gross proceeds of C$5.4 million.	75.39%
	SciSparc Invests C$2.7 Million In NeuroThera Financing, Raising Stake To 44.6% Valued At ~C$30 Million	94.21%
	SciSparc Unit Neurothera Labs Receives Japanese Patent For Its Pharmacological Combination Titled 'Compositions And Methods For Potentiating Derivatives Of 4-Aminophenols'	93.01%
	SciSparc's NeuroThera Labs Initiates Phase IIb Clinical Study To Evaluate SCI-110 Drug Candidate To Treat Tourette Syndrome	56.62%